The Quantellect read.As of Nov 19, 2026, 18 active firms cover Jazz Pharmaceuticals PLC: 17 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $225.00 to $337.00, a moderate spread. The average target of $294.50 sits 19% above the current $247.91. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 15 to 17 over recent months. On the fundamentals, the Street sees consensus EPS building from about $5.89 next quarter toward $26.71 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS18 active firms
Buy
Strong Buy00%
Buy1794%
Neutral16%
Sell00%
Strong Sell00%
Based on 18 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$294.50
+18.8% upside
Average target across 18 active firms as of Nov 19, 2026 vs $247.91 current
Highest Target$337.00
Average Target$294.50
Lowest Target$225.00
Detailed analyst forecasts for JAZZ
Showing 1–20 of 20 named analysts shown · 18 active firms in the rating projection
As of Nov 19, 2026, 17 of 18 active firms rate JAZZ a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
JAZZ EPS & revenue forecast
EPS · NEXT QUARTER
$5.89
Range $4.88 – $7.32 · 7 analysts · -7% YoY
Next period, 7 analysts expect Jazz Pharmaceuticals PLC to earn $5.89 a share (range $4.88 – $7.32), versus $6.34 a year earlier. Full-year consensus is $14.95, growing to $26.71 the year after.
REVENUE · NEXT QUARTER
$1.1B
Range $1.1B – $1.2B · 7 analysts · +6% YoY
Revenue is expected to reach $1.1B (range $1.1B – $1.2B), +6.3% year-over-year. Full-year consensus is $4.8B, rising to $5.1B next year.
Top analysts covering Jazz Pharmaceuticals PLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on JAZZ.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #10
Buy
$322.00+29.9% to target
Overall win rate
64%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #27
Buy
$305.00+23.0% to target
Overall win rate
52%
+ Follow
#3
Joel Beatty
Baird · Rank #71
Buy
$280.00+12.9% to target
Overall win rate
50%
+ Follow
#4
Ami Fadia
Needham · Rank #92
Buy
$310.00+25.0% to target
Overall win rate
46%
+ Follow
#5
Jessica Fye
JP Morgan · Rank #100
Buy
$310.00+25.0% to target
Overall win rate
54%
+ Follow
JAZZ stock forecast FAQ
What is JAZZ's average 12-month price target?+
The 18 active firms with a live target average $294.50 for Jazz Pharmaceuticals PLC over the next 12 months, ranging from a $337.00 high to a $225.00 low, as of Nov 19, 2026.
Is JAZZ stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 18 active firms as of Nov 19, 2026, 17 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for JAZZ?+
The Street-high target is $337.00 (Goldman Sachs), and the Street-low is $225.00 (Leerink Partners). The average of all 18 active-firm targets is $294.50.
How many active Wall Street firms cover JAZZ?+
18 active firms have a recognized rating on Jazz Pharmaceuticals PLC as of Nov 19, 2026, and 18 active firms carry a live 12-month price target.
Who is the most accurate analyst covering JAZZ?+
Among analysts who currently cover JAZZ, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #10). Their current call is Buy with a $322.00 target.
What is Jazz Pharmaceuticals PLC's projected EPS for next quarter?+
The consensus estimate is $5.89 per share (range $4.88 – $7.32) across 7 analysts. Full-year EPS is projected at $14.95, rising to $26.71 the following year.
How much revenue is Jazz Pharmaceuticals PLC expected to report next quarter?+
Consensus revenue is $1.1B (range $1.1B – $1.2B). Full-year revenue is projected at $4.8B, growing to $5.1B next year.
Have analysts been upgrading or downgrading JAZZ lately?+
As of Nov 19, 2026, 17 of 18 active firms rate JAZZ a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their JAZZ calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.